BACKGROUND AND OBJECTIVES: Current guidelines recommend 24-hour urine testing in the evaluation and treatment of persons with high-risk urinary stone disease. However, how much clinicians use information from 24-hour urine testing to guide secondary prevention strategies is unknown. We sought to determine the degree to which clinicians initiate or continue stone disease-related medications in response to 24-hour urine testing. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We examined a national cohort of 130,489 patients with incident urinary stone disease in the Veterans Health Administration between 2007 and 2013 to determine whether prescription patterns for thiazide diuretics, alkali therapy, and allopurinol changed in response to 24-hour urine testing. RESULTS: Stone formers who completed 24-hour urine testing (n=17,303; 13%) were significantly more likely to be prescribed thiazide diuretics, alkali therapy, and allopurinol compared with those who did not complete a 24-hour urine test (n=113,186; 87%). Prescription of thiazide diuretics increased in patients with hypercalciuria (9% absolute increase if urine calcium 201-400 mg/d; 21% absolute increase if urine calcium >400 mg/d, P<0.001). Prescription of alkali therapy increased in patients with hypocitraturia (24% absolute increase if urine citrate 201-400 mg/d; 34% absolute increase if urine citrate ≤200 mg/d, P<0.001). Prescription of allopurinol increased in patients with hyperuricosuria (18% absolute increase if urine uric acid >800 mg/d, P<0.001). Patients who had visited both a urologist and a nephrologist within 6 months of 24-hour urine testing were more likely to have been prescribed stone-related medications than patients who visited one, the other, or neither. CONCLUSIONS: Clinicians adjust their treatment regimens in response to 24-hour urine testing by increasing the prescription of medications thought to reduce risk for urinary stone disease. Most patients who might benefit from targeted medications remain untreated.
BACKGROUND AND OBJECTIVES: Current guidelines recommend 24-hour urine testing in the evaluation and treatment of persons with high-risk urinary stone disease. However, how much clinicians use information from 24-hour urine testing to guide secondary prevention strategies is unknown. We sought to determine the degree to which clinicians initiate or continue stone disease-related medications in response to 24-hour urine testing. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We examined a national cohort of 130,489 patients with incident urinary stone disease in the Veterans Health Administration between 2007 and 2013 to determine whether prescription patterns for thiazide diuretics, alkali therapy, and allopurinol changed in response to 24-hour urine testing. RESULTS: Stone formers who completed 24-hour urine testing (n=17,303; 13%) were significantly more likely to be prescribed thiazide diuretics, alkali therapy, and allopurinol compared with those who did not complete a 24-hour urine test (n=113,186; 87%). Prescription of thiazide diuretics increased in patients with hypercalciuria (9% absolute increase if urine calcium 201-400 mg/d; 21% absolute increase if urine calcium >400 mg/d, P<0.001). Prescription of alkali therapy increased in patients with hypocitraturia (24% absolute increase if urine citrate 201-400 mg/d; 34% absolute increase if urine citrate ≤200 mg/d, P<0.001). Prescription of allopurinol increased in patients with hyperuricosuria (18% absolute increase if urine uric acid >800 mg/d, P<0.001). Patients who had visited both a urologist and a nephrologist within 6 months of 24-hour urine testing were more likely to have been prescribed stone-related medications than patients who visited one, the other, or neither. CONCLUSIONS: Clinicians adjust their treatment regimens in response to 24-hour urine testing by increasing the prescription of medications thought to reduce risk for urinary stone disease. Most patients who might benefit from targeted medications remain untreated.
Authors: Jonathan S Ellison; Samuel R Kaufman; Kate H Kraft; J Stuart Wolf; Brent K Hollenbeck; John M Hollingsworth Journal: Urology Date: 2014-06-21 Impact factor: 2.649
Authors: Jaclyn C Milose; Samuel R Kaufman; Brent K Hollenbeck; J Stuart Wolf; John M Hollingsworth Journal: J Urol Date: 2013-09-07 Impact factor: 7.450
Authors: Margaret S Pearle; David S Goldfarb; Dean G Assimos; Gary Curhan; Cynthia J Denu-Ciocca; Brian R Matlaga; Manoj Monga; Kristina L Penniston; Glenn M Preminger; Thomas M T Turk; James R White Journal: J Urol Date: 2014-05-20 Impact factor: 7.450
Authors: Kiriaki K Stamatelou; Mildred E Francis; Camille A Jones; Leroy M Nyberg; Gary C Curhan Journal: Kidney Int Date: 2003-05 Impact factor: 10.612
Authors: Casey A Dauw; Abdulrahman F Alruwaily; Maggie J Bierlein; John R Asplin; Khurshid R Ghani; J Stuart Wolf; John M Hollingsworth Journal: J Urol Date: 2014-10-05 Impact factor: 7.450
Authors: Ryan S Hsi; Phyllis L Yan; Joseph J Crivelli; David S Goldfarb; Vahakn Shahinian; John M Hollingsworth Journal: Urology Date: 2022-02-17 Impact factor: 2.633
Authors: James C Williams; Giovanni Gambaro; Allen Rodgers; John Asplin; Olivier Bonny; Antonia Costa-Bauzá; Pietro Manuel Ferraro; Giovanni Fogazzi; Daniel G Fuster; David S Goldfarb; Félix Grases; Ita P Heilberg; Dik Kok; Emmanuel Letavernier; Giuseppe Lippi; Martino Marangella; Antonio Nouvenne; Michele Petrarulo; Roswitha Siener; Hans-Göran Tiselius; Olivier Traxer; Alberto Trinchieri; Emanuele Croppi; William G Robertson Journal: Urolithiasis Date: 2020-10-13 Impact factor: 3.436